Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer (vol 24, pg 638, 2018)

被引：0
|
作者：
Robichaux, Jacqulyne P.
Elamin, Yasir Y.
Tan, Zhi
Carter, Brett W.
Zhang, Shuxing
Liu, Shengwu
Li, Shuai
Chen, Ting
Poteete, Alissa
Estrada-Bernal, Adriana
Le, Anh T.
Truini, Anna
Nilsson, Monique B.
Sun, Huiying
Roarty, Emily
Goldberg, Sarah B.
Brahmer, Julie R.
Altan, Mehmet
Lu, Charles
Papadimitrakopoulou, Vassiliki
Politi, Katerina
Doebele, Robert C.
Wong, Kwok-Kin
Heymach, John V.
机构：
[1] University of Texas MD Anderson Cancer Center,Department of Thoracic Head and Neck Medical Oncology
[2] University of Texas MD Anderson Cancer Center,Department of Experimental Therapeutics
[3] University of Texas MD Anderson Cancer Center,Department of Diagnostic Radiology
[4] Dana-Farber Cancer Institute,Lowe Center for Thoracic Oncology
[5] University of Colorado Cancer Center,Yale Cancer Center
[6] Yale University School of Medicine,Department of Medicine
[7] Yale University School of Medicine,Sidney Kimmel Comprehensive Cancer Center
[8] Johns Hopkins University,Department of Pathology
[9] Yale University School of Medicine,Laura & Isaac Perlmutter Cancer Center
[10] New York University Langone Medical Center,undefined
来源：
NATURE MEDICINE | 2024年
关键词：
D O I：
10.1038/s41591-024-03178-1
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：2694 / 2695
页数：2
相关论文
共 50 条
  • [41] Plasma EGFR and Her2 levels in non-small cell lung cancer patients treated with gefitinib
    Kasahara, K.
    Tamori, S.
    Sakai, A.
    Tambo, Y.
    Araya, T.
    Sone, T.
    Kimura, H.
    Fujimura, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Uzunbas, Gizem Karsli
    McVeigh, Quinn
    Gupta, Akansha
    Hoyt, Stephanie
    Doucette, Kristen
    Keshishian, Hasmik
    Carr, Steven
    Yang, Xiaoping
    Root, David
    Cherniack, Andrew D.
    Siegel, Franziska
    Siegel, Stephan
    Meyerson, Matthew
    Greulich, Heidi
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [43] Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Uzunbas, Gizem Karsli
    McVeigh, Quinn
    Gupta, Akansha
    Hoyt, Stephanie
    Cherniack, Andrew
    Siegel, Franziska
    Siegel, Stephan
    Meyerson, Matthew
    Greulich, Heidi
    CANCER RESEARCH, 2023, 83 (07)
  • [44] Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer
    Huang, Wei-Sheng
    Li, Feng
    Gong, Yongjin
    Zhang, Yun
    Youngsaye, Willmen
    Xu, Yongjin
    Zhu, Xiaotian
    Greenfield, Matthew T.
    Kohlmann, Anna
    Taslimi, Paul M.
    Toms, Angela
    Zech, Stephan G.
    Zhou, Tianjun
    Das, Biplab
    Jang, Hyun G.
    Tugnait, Meera
    Ye, Yihua E.
    Gonzalvez, Francois
    Baker, Theresa E.
    Nadworny, Sara
    Ning, Yaoyu
    Wardwell, Scott D.
    Zhang, Sen
    Gould, Alexandra E.
    Hu, Yongbo
    Lane, Weston
    Skene, Robert J.
    Zou, Hua
    Clackson, Tim
    Narasimhan, Narayana I.
    Rivera, Victor M.
    Dalgarno, David C.
    Shakespeare, William C.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 80
  • [45] Activity of Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance
    Koga, T.
    Kobayashi, Y.
    Tomizawa, K.
    Sesumi, Y.
    Fujino, T.
    Nishino, M.
    Ohara, S.
    Chiba, M.
    Shimoji, M.
    Suda, K.
    Takemoto, T.
    Mitsudomi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S598 - S599
  • [46] Investigation of HER2 overexpression in non-small cell lung cancer
    Ugocsai, K
    Mándoky, L
    Tiszlavicz, L
    Molnár, J
    ANTICANCER RESEARCH, 2005, 25 (04) : 3061 - 3066
  • [47] Targeting HER2 in the treatment of non-small cell lung cancer
    Mar, Nataliya
    Vredenburgh, James J.
    Wasser, Jeffrey S.
    LUNG CANCER, 2015, 87 (03) : 220 - 225
  • [48] EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
    Chelabi, Samy
    Mignard, Xavier
    Leroy, Karen
    Monnet, Isabelle
    Brosseau, Solenn
    Theou-Anton, Nathalie
    Massiani, Marie-Ange
    Friard, Sylvie
    Duchemann, Boris
    Fabre, Elizabeth
    Giroux-Leprieur, Etienne
    Cadranel, Jacques
    Wislez, Marie
    CANCERS, 2021, 13 (20)
  • [49] Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer: Single-Institution Experience
    Lee, So Heun
    Jeong, Hyehyun
    Kim, Deok Hoon
    Jang, Se Jin
    Kim, Sang-We
    Yoon, Shinkyo
    Lee, Dae Ho
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 774 - 784
  • [50] Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions.
    Ou, Sai-Hong Ignatius
    Madison, Russell
    Robichaux, Jacqulyne Ponville
    Ross, Jeffrey S.
    Miller, Vincent A.
    Ali, Siraj Mahamed
    Schrock, Alexa Betzig
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345